Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EPS (Basic) (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed EPS (Basic) for 16 consecutive years, with $0.01 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 89.04% year-over-year to $0.01, compared with a TTM value of -$0.09 through Dec 2025, up 50.0%, and an annual FY2025 reading of -$0.09, up 50.0% over the prior year.
  • EPS (Basic) was $0.01 for Q4 2025 at Amicus Therapeutics, down from $0.06 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.06 in Q3 2025 and bottomed at -$0.3 in Q1 2022.
  • Average EPS (Basic) over 5 years is -$0.12, with a median of -$0.11 recorded in 2023.
  • Peak annual rise in EPS (Basic) hit 400.0% in 2025, while the deepest fall reached 89.04% in 2025.
  • Year by year, EPS (Basic) stood at -$0.29 in 2021, then skyrocketed by 33.36% to -$0.19 in 2022, then skyrocketed by 43.08% to -$0.11 in 2023, then surged by 145.45% to $0.05 in 2024, then tumbled by 89.04% to $0.01 in 2025.
  • Business Quant data shows EPS (Basic) for FOLD at $0.01 in Q4 2025, $0.06 in Q3 2025, and -$0.08 in Q2 2025.